Introduction {#Sec1}
============

Prostate cancer (PCa) is one of the most frequently diagnosed cancers among men and is the second leading cause of male cancer-related deaths^[@CR1]^. PCa progresses in an androgen-dependent manner and responds to hormone deprivation/ablation therapy that subsequently removes circulating androgens and reduces androgen action^[@CR2]^. However, many patients do not respond well to this treatment and even progress to an androgen-independent state, which is more aggressive and treatment resistant^[@CR3]^. Despite an increasing use of prostate-specific antigen (PSA)-based screening for early detection of PCa at a curable stage, determining which patients require treatment and what types of therapy should be performed remain challenging. More efficient and novel biomarkers should be identified and used to confirm the malignant potentials of PCa to predict patient clinical outcome, evaluate the risk of recurrence and select optimized therapeutic strategies.

Accumulating studies have identified multiple dysregulated microRNAs (miRNAs), which are hallmark characteristics during prostate carcinogenesis^[@CR4]--[@CR6]^. However, the complexity of how a single miRNA can play numerous roles in carcinogenesis, specifically in PCa, has not been fully elucidated.

Ribonuclease L (RNASEL), which is located on chromosome 1q25a, is a uniquely regulated endoribonuclease that is involved in the cleavage of viral RNA and the interferon-mediated immune response^[@CR7]^. Several population-based case-control studies have investigated the associations between RNASEL variants and PCa risk^[@CR8]--[@CR10]^. These findings suggest that RNASEL may play a crucial role in PCa. However, little is known about the underlying molecular mechanisms through which RNASEL affects PCa.

Our recent study identified 26 differentially expressed miRNAs between PCa and adjacent benign tissues obtained from PCa patients^[@CR6]^. To identify the crucial miRNAs based on this previous miRNA expression profile in PCa and their target genes and to decipher the potential relationship between the changes in the expression of these miRNAs and RNASEL, we proposed an integrated systematic approach to illustrate an miRNA-mediated gene expression regulatory network, discover crucial miRNA-target negative regulation pairs with network topological importance, validate their biological functions based on in vitro and in vivo experimental systems and evaluate their clinical significance in human PCa. A schematic diagram of this study is provided in Supplementary Figure [S1](#MOESM3){ref-type="media"}.

Results {#Sec2}
=======

Signal axis screening of the miRNA-mediated regulatory network of PCa {#Sec3}
---------------------------------------------------------------------

### Signal axis screening {#Sec4}

In our previous study, 26 differentially expressed miRNAs, including 9 upregulated and 17 downregulated miRNAs (all fold change ≥ 1.5; *P* ≤ 0.05), were identified through a comparison of PCa and adjacent benign prostate tissues^[@CR6]^. Detailed information for these differentially expressed miRNAs is provided in Supplementary Table [S1](#MOESM14){ref-type="media"}. The common results of three miRNA target-predicting programs (TargetScan, miRWalk, and miRanda) identified 593 candidate miRNA--mRNA pairs based on the putative interactions between differentially expressed miRNAs and target genes as well as between miRNAs and RNASEL, as shown in Supplementary Table [S2](#MOESM15){ref-type="media"}. The biological significance of these miRNA--mRNA pairs is provided in Supplementary File [S1](#MOESM2){ref-type="media"}---section [1](#MOESM2){ref-type="media"} and Figure [S2](#MOESM4){ref-type="media"}.

A miRNA-mediated regulatory network of PCa was constructed using the links among putative target genes of differentially expressed miRNAs and RNASEL-upstream miRNAs. This network contained 243 nodes and 1167 edges (Supplementary Table [S3](#MOESM16){ref-type="media"}). Following the calculation of four topological features, including 'Degree,' 'Node betweenness' and 'Closeness' and 'K coreness,' 89 hubs with topological importance were chosen, and the hub network was also constructed based on the direct interactions among hubs. Detailed information about the topological features of the hubs is provided in Supplementary Table [S4](#MOESM17){ref-type="media"}.

Because genes with close interconnections are often involved in the same functional modules or pathways, modularity may be another important aspect of an interaction network. In the current study, we performed modularity analysis using the Markov clustering algorithm and divided the above-mentioned hub network into the following three functional modules: 'Cell cycle, Pathways in cancer, and P53 signaling pathway' (48 nodes); 'MAPK signaling pathway and Focal adhesion' (38 nodes); and 'VEGF signaling pathway' (3 nodes) (Supplementary Figure [S3](#MOESM5){ref-type="media"}).

Moreover, the 'Edge-betweenness' of each interaction in the hub network was calculated because an interaction with a high 'Edge-betweenness' is defined as a bottleneck that has many 'shortest paths' going through it and controls the rate of information flow. As shown in Supplementary Table [S5](#MOESM18){ref-type="media"}, the interaction between CCND1-CDKN1A had the highest 'Edge-betweenness' value (40.10), implying its importance in connecting different functional modules within the network.

Among the putative targets of differentially expressed miRNAs in PCa, TP73 was a putative target of miR-193a-5p (PCa-downregulated miRNA, Supplementary Table [S1](#MOESM14){ref-type="media"}) and interacted with CDKN1A. Additionally, UBE2I was a putative target of miR-188-5p (PCa-upregulated miRNA, Supplementary Table [S1](#MOESM14){ref-type="media"}) and interacted with TP73 and CDKN1A through MDM2 (Fig. [1a](#Fig1){ref-type="fig"}). Moreover, we also found 17 miRNAs that act upstream of RNASEL and were shared with CCND1 and/or CDKN1A, implying similar functions among the three genes (Fig. [1a](#Fig1){ref-type="fig"}). Thus, we hypothesized that the signal axis of CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I might play a crucial role in the miRNA-mediated regulatory network of human PCa.Fig. 1Involvement of the miR-193a-5p and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal axis in prostate cancer (PCa) cells.**a** Sub-network of the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal axis and the corresponding upstream microRNAs. Nodes with a red border refer to an upregulated microRNA in PCa. Nodes with a blue border refer to a downregulated microRNA in PCa. Nodes with a yellow border refer to common microRNAs upstream of CCND1, RNASEL and CDKN1A. **b** Molecular model of the miR-193a-5p and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal axis in PCa cells

### Biological significance of the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal axis {#Sec5}

Cyclin D1 (CCND1) is amplified and overexpressed in a variety of human malignancies, including human PCa^[@CR11],[@CR12]^. In accordance with the androgen dependence of PCa, CCND1 interacts with the androgen signaling pathway, suggesting that androgens may indirectly stimulate cell growth via regulating the expression of cell cycle-associated genes^[@CR13]^.

CDKN1A (also called p21), which is a CDK inhibitor (CKI), can suppress the effects of the CCND1-CDK4 complex in the G1 phase, leading to G1 arrest. Importantly, p21 activation requires high levels of tumor protein p73 (TP73)^[@CR14]^.

TP73 encodes a variety of protein isoforms with opposing functions via alternative promoters at the 5′-end or differential splicing at the 3′-end^[@CR15],[@CR16]^. Among the isoforms, TAp73 variants, which contain the NH2-terminal transactivation domain, are tumor suppressors and mimic TP53 function in experimental systems. In contrast, deltaNp73 variants, which are transactivation-deficient isoforms, function as oncogenes and cannot induce apoptosis and cell cycle arrest because they are direct competitors for the DNA-binding sites and/or they form hetero-duplexes with TP53 and the transactivation-competent TAp73 variants^[@CR17]^. Hence, the biological functions of miRNAs that directly target TP73 may depend on which isoforms they mainly regulate. Moreover, Guan et al.^[@CR18]^ observed a significant increase of deltaNp73 in PCa tissues compared with benign prostate hyperplasia tissues and confirmed that the incidence of positive expression of deltaNp73 is correlated with the Gleason score in PCa.

RNASEL regulates p21-mediated G1 growth arrest in an AU-rich element-dependent manner. Overexpression of RNASEL may activate p21^[@CR19]^.

Ubiquitin-conjugating enzyme E2 I (UBE2I) encodes a member of the E2 ubiquitin-conjugating enzyme family (UBC9), which may modify proteins with ubiquitin, a crucial cellular mechanism for targeting abnormal or short-lived proteins for degradation. A previous study based on a yeast two-hybrid system found that RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I^[@CR20]^.

We illustrated a model to hypothesize the involvement of the miR-193a-5p-regulated and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal axis in prostate carcinogenesis (Fig. [1b](#Fig1){ref-type="fig"}). In PCa tissues, the increased expression of miR-188-5p may negatively regulate the expression of its candidate target gene, UBE2I, which may reduce the degradation of TP73. Simultaneously, the downregulation of miR-193a-5p in PCa tissues might result in the upregulation of TP73. Because there are different isoforms of TP73 with varying potential for tumor progression, TP73 may play opposite roles depending on changes in the TAp73/ deltaNp73 isoform ratio. If the TAp73/deltaNp73 isoform ratio is increased by miR-193a-5p in PCa cells, the expression levels of MDM2 and P21 (CDKN1A) might be elevated, and TP73 might function as a tumor suppressor, leading to the reduced effect of the CCND1/CDK4 complex and G1 arrest. If the TAp73/deltaNp73 isoform ratio is decreased by miR-193a-5p in PCa cells, the expression levels of MDM2 and P21 (CDKN1A) might be reduced, and TP73 might function as an oncogene. Taken together, an imbalance of the miR-193a-5p- and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I biomodule might be involved in prostate carcinogenesis.

Deregulation of miR-193a-5p-TP73 and miR-188-5p-UBE2I pairs associated with aggressive progression and poor prognosis in PCa patients {#Sec6}
-------------------------------------------------------------------------------------------------------------------------------------

To evaluate the associations of miR-193a-5p-TP73 and miR-188-5p-UBE2I expression with various clinicopathological features of PCa patients, the optimal cutoff points of miR-193a-5p, TP73, miR-188-5p and UBE2I expression were screened. The optimal cutoff point was defined with regard to the miRNA/mRNA expression level either alone or in combination with the most significant BCR-free survival. Using the optimal cutoff points, 490 PCa patients were divided into miR-193a-5p-high/low, TP73-high/low, miR-188-5p-high/low and UBE2I-high/low groups. As shown in Table [1](#Tab1){ref-type="table"}, high TP73 expression was significantly associated with disease-free status (*P* = 0.042), and low miR-193a expression combined with high TP73 expression frequently occurred in PCa patients with advanced T-stage (*P* = 0.047) and positive disease recurrence (*P* = 0.031). In addition, PCa patients with high miR-188-5p or low UEB2I expression had a higher incidence of biochemical recurrence than those with low miR-188-5p or high UBE2I expression (both *P* \< 0.05). Gleason grades of PCa patients with high miR-188-5p expression and miR-188-5p-high/UBE2I-low expression were significantly higher than those of patients with low miR-188-5p expression and miR-188-5p-low/UBE2I-high expression, respectively (both *P* \< 0.05). Both low UBE2I expression and combined miR-188-5p-high/UBE2I-low expression were significantly associated with advanced T stage (both *P* \< 0.05). PCa patients with miR-188-5p-high/UBE2I-low expression frequently experienced advanced N stage and recurred/progressed disease status (both *P* \< 0.05, Table [1](#Tab1){ref-type="table"}).Table 1Association of two miRNA--mRNA pairs with clinicopathologic features of prostate cancer patients based on TCGA dataClinical featuresCase No.^a^miR-193a-lowTP73-highmiR-193a-low/TP73-highmiR-188-highUBE2I-lowmiR-188-high/UBE2I-low(*n*, %)*P*(*n*, %)*P*(*n*, %)*P*(*n*, %)*P*(*n*, %)*P*(*n*, %)*PAge (years)*\<558318 (21.7)0.88356 (67.5)0.26513 (37.1)0.42240 (48.2)0.69838 (45.8)0.16219 (43.3)0.405\>5540685 (20.9)245(60.3)53 (29.1)204 (50.2)206 (50.7)101 (51.3)*Biochemical-recurrence status*Negative36578 (21.4)0.499227 (62.2)1.00048 (30.8)0.516160 (43.8)0.033167 (45.8)0.03579 (45.9)1.000Positive5915 (25.4)37 (62.7)11 (37.9)40 (67.8)40 (67.8)14 (46.7)*Gleason pattern (Primary)*Grade 319134 (17.8)0.310120 (62.8)0.11420 (26.0)0.27578 (40.8)0.01898 (51.3)0.10044 (44.4)\<0.001Grade 424859 (23.8)144 (58.1)36 (30.8)129 (52.0)116 (46.8)60 (48.0)Grade 54910 (20.4)36 (73.5)10 (43.5)38 (77.6)30 (61.2)16 (100.0)*T-stage*\<T217630 (17.0)0.210105 (59.7)0.29916 (21.9)0.04787 (49.4)0.38675 (42.6)0.00339 (42.4)0.007\>T222651 (22.6)147 (65.0)39 (36.8)113 (50.0)140 (61.9)69(62.2)*N-stage*N033971 (20.9)0.545207 (61.1)0.79844 (29.5)0.342168 (49.6)0.882165 (48.7)0.06172 (43.6)\<0.001N17919 (24.1)50 (63.3)15 (37.5)40 (50.6)46 (58.2)28(82.4)*Disease-free status*Free39279 (20.2)0.318233 (59.4)0.04248 (27.3)0.031189 (48.2)0.562188 (48.0)0.05289 (46.6)0.038Recurred/progressed9123 (25.3)65 (71.4)17 (45.9)52 (57.1)56 (61.5)32 (64.0)^a^ Some clinical features lack the information, so the total numbers according to various features are different

The prognostic values of miR-193a-5p and/or TP73 expression as well as miR-188-5p and/or UBE2I expression in PCa patients were evaluated using the Kaplan--Meier method based on TCGA data. As shown in Fig. [2h, i](#Fig2){ref-type="fig"}, high TP73 expression alone or in combination with low miR-193a expression were both significantly associated with short BCR-free survival when compared with low TP73 expression (*P* = 0.036) and miR-193a-5p-high /TP73-low expression (*P* = 0.033) groups, respectively. Moreover, only miR-188-5p-high/UBE2I-low expression was significantly associated with short BCR-free survival (*P* = 0.045, log-rank test, Fig. [2l](#Fig2){ref-type="fig"}). There were no significant prognostic values of miR-193a-5p/TP73 and miR-188-5p/UBE2I axes in overall and disease metastasis-free survivals (Fig. [2a--f](#Fig2){ref-type="fig"} and Fig. [2m--r](#Fig2){ref-type="fig"}).Fig. 2Overall survival (**a--f**), biochemical recurrence (BCR)-free survival (**g--l**) and distant-metastasis-free survival (**m--r**) curves based on miR-193a and/or TP73 as well as miR-188 and/or UBE2I expression in patients with prostate cancer based on TCGA data

TP73 and UBE2I are respective direct targets of miR-193a-5p and miR-188-5p in PCa cells {#Sec7}
---------------------------------------------------------------------------------------

The results shown in Supplementary Figure [S4A](#MOESM6){ref-type="media"} indicated that the endogenous expression of TP73 in PCa cells and in established tumors associated with LNCaP cells stably expressing miR-193a-5p was significantly reduced at both the mRNA and protein levels. In contrast, knockdown of miR-193a-5p by its inhibitor efficiently increased the expression of TP73 mRNA and protein in both PCa cells and established tumors (Supplementary Figure [S4A](#MOESM6){ref-type="media"}). The findings for the miR-188-5p/UBE2I pair were similar to those for the miR-193a-5p/TP73 pair (Supplementary Figure [S4B](#MOESM6){ref-type="media"}). Because TP73 has various isoforms with opposing functions, we performed qRT-PCR to evaluate the regulatory effects of miR-193a-5p on a tumor promoter isoform of TP73 (deltaNp73) and a tumor suppressive isoform of TP73 (TAp73). As shown in Supplementary Figure [S5](#MOESM7){ref-type="media"}, the enforced expression of miR-193a-5p in PCa cells effectively reduced the expression of deltaNp73 mRNA and increased the ratio of TAp73 to deltaNp73. In contrast, the suppression of miR-193a-5p upregulated the expression of deltaNp73 mRNA and decreased the ratio of TAp73 to deltaNp73. These results suggest a more significant regulatory effect of miR-193a-5p on deltaNp73 than on TAp73.

To verify whether TP73 was a direct target of miR-193a-5p, and UBE2I was a direct target of miR-188-5p, a luciferase reporter containing the complimentary seed sequences of miR-193a-5p/miR-188-5p at the 3′-UTR region of TP73 (Transcript NM_001126242, protein name: deltaNp73 gamma) /UBE2I (Transcript NM_003345) mRNA was constructed. At 48 h after transfection, luciferase activity of the TP73 reporter was significantly reduced by co-transfection with miR-193a-5p mimics. In contrast, the luciferase activity of the TP73 reporter containing the mutated sequence of the same fragment was not affected by co-transfection with miR-193a-5p mimics (Supplementary Figure [S6A](#MOESM8){ref-type="media"}). These findings were similar with those for the miR-188-5p/UBE2I pair (Supplementary Figure [S6B](#MOESM8){ref-type="media"}).

The above data suggest that TP73 and UBE2I may be direct targets of miR-193a-5p and miR-188-5p, respectively, in PCa cells.

miR-193a-5p functions as a tumor suppressor in PCa via targeting TP73 {#Sec8}
---------------------------------------------------------------------

CCK-8 assays indicated that proliferation rate of LNCaP and PC3 cells transfected with miR-193a-5p mimics was significantly lower than those transfected with the negative control (Fig. [3a](#Fig3){ref-type="fig"} and Supplementary Figure [S7A](#MOESM9){ref-type="media"}). Transwell assays showed that the enforced expression of miR-193a-5p significantly reduced the invasive activities of both LNCaP and PC3 cells (Fig. [3b](#Fig3){ref-type="fig"} and Supplementary Figure [S7B](#MOESM9){ref-type="media"}). Wound-healing assays also revealed that miR-193a-5p overexpression efficiently weakened the migratory abilities of both LNCaP and PC3 cells (Fig. [3c](#Fig3){ref-type="fig"} and Supplementary Figure [S7C](#MOESM9){ref-type="media"}). Based on the in vivo system, we found that the LNCaP cells stably expressing miR-193a-5p formed significantly smaller tumor nodules and showed markedly slow growth of tumor xenografts (Fig. [3d](#Fig3){ref-type="fig"}). In contrast, the apoptotic rates of LNCaP and PC3 cells with miR-193a-5p upregulation were significantly higher than those of control cells (Fig. [3e](#Fig3){ref-type="fig"} and Supplementary Figure [S7D](#MOESM9){ref-type="media"}). Interestingly, knockdown of miR-193a-5p expression by the corresponding inhibitor efficiently enhanced the cellular proliferation, invasion ability and motility of PCa cells and promoted the growth of tumor xenografts; it reduced cellular apoptosis in vitro (Fig. [3f--j](#Fig3){ref-type="fig"} and Supplementary Figure [S7E--H](#MOESM9){ref-type="media"}).Fig. 3miR-193a-5p inhibits LNCaP cell proliferation, migration and invasion and in vivo tumor growth, but it induces LNCaP cell apoptosis.**a** The CCK-8 assay indicated that proliferation of LNCaP cells transfected with miR-193a-5p mimics was significantly reduced compared with that of cells transfected with the negative control. **b** The transwell assay showed that the enforced expression of miR-193a-5p significantly reduced the invasive activities of LNCaP cells compared with those of control cells. **c** The wound-healing assay revealed that miR-193a-5p overexpression efficiently weakened the migratory ability of LNCaP cells. **d** Based on the in vivo system, LNCaP cells stably expressing miR-193a-5p formed significantly smaller tumor nodules and showed markedly slow growth of tumor xenografts compared with the controls. **e** The apoptotic rate of LNCaP cells with miR-193a-5p upregulation was significantly higher than that of control cells. **f--j** Knockdown of miR-193a-5p expression with the corresponding inhibitor efficiently enhanced the cellular proliferation, invasion ability and motility of LNCaP cell lines and promoted the growth of tumor xenografts, but it reduced cellular apoptosis in vitro. Note: '×10' and '×20' refer to the magnification

To determine the roles of TP73 in biological functions of miR-193a-5p, pCDNA3.1(+) vectors expressing TP73 without its 3′-UTR (using the binding site of 3′UTR of Transcript NM_001126242, the protein name of which is deltaNp73 gamma) were generated. As shown in Fig. [4a](#Fig4){ref-type="fig"} and Supplementary Figure [S8A](#MOESM10){ref-type="media"}, the endogenous expression of TP73 protein in LNCaP and PC3 cells transfected with miR-193a-5p mimics in the presence of pCDNA3.1-TP73 was significantly higher than that in cells transfected with miR-193a-5p and vector control. In vitro cellular proliferation (Fig. [4b](#Fig4){ref-type="fig"} and Supplementary Figure [S8B](#MOESM10){ref-type="media"}), invasion (Fig. [4c](#Fig4){ref-type="fig"} and Supplementary Figure [S8C](#MOESM10){ref-type="media"}), migration (Fig. [4d](#Fig4){ref-type="fig"} and Supplementary Figure [S8D](#MOESM10){ref-type="media"}) and apoptosis (Fig. [4e](#Fig4){ref-type="fig"} and Supplementary Figure [S8E](#MOESM10){ref-type="media"}) all indicated that restoration of TP73 expression dramatically attenuated the effects induced by miR-193a-5p.Fig. 4Re-expression of TP73 rescues the tumor suppressive effects of miR-193a-5p in LNCaP cells.**a** Endogenous TP73 protein expression levels were detected by western blotting in LNCaP cells transfected with the miR-193a-5p mimic in the presence of TP73 or vector control for 48 h. **b--e** Expression of TP73 using a construct lacking its 3′-UTR rescued the biological effects associated with re-introduction of miR-193a-5p, as indicated by cell invasion, viability, migration and apoptosis assays. These experiments were performed after transfection of miR-193a-5p mimics and/or the TP73 3′-UTR (−) for 48 h. The data are representative of at least three independent experiments and are presented as the mean ± s.e.m. Note: '×10' and '×20' refer to the magnification

These findings suggest that the tumor suppressive roles of miR-193a-5p may be mediated by inhibiting its target gene, TP73.

miR-188-5p functions as an onco-miRNA in PCa by targeting UBE2I {#Sec9}
---------------------------------------------------------------

CCK-8 assays indicated that proliferation rates of LNCaP and PC3 cells were significantly increased by transfection with miR-188-5p mimics (Fig. [5a](#Fig5){ref-type="fig"} and Supplementary Figure [S9A](#MOESM11){ref-type="media"}). Transwell and wound-healing assays showed that the enforced expression of miR-188-5p dramatically enhanced the invasive and migratory activities, respectively, of both LNCaP and PC3 cells (Figure [5b, c](#MOESM1){ref-type="media"} and Supplementary Figure [S9B, C](#MOESM11){ref-type="media"}). Based on the in vivo system, miR-188-5p overexpression promoted tumor growth (Fig. [5d](#Fig5){ref-type="fig"}). In contrast, the apoptotic rates of LNCaP and PC3 cells with miR-188-5p upregulation were significantly lower than those of control cells (Fig. [5e](#Fig5){ref-type="fig"} and Supplementary Figure [S9D](#MOESM11){ref-type="media"}). Interestingly, knockdown of miR-188-5p expression by the corresponding inhibitor reduced the enhanced effects on cellular proliferation, invasion and motility of PCa cell lines and the growth of tumor xenografts, but it increased cellular apoptosis in vitro (Fig. [5f--j](#Fig5){ref-type="fig"} and Supplementary Figure [S9E--H](#MOESM11){ref-type="media"}).Fig. 5miR-188-5p promotes LNCaP cell proliferation, migration and invasion and in vivo tumor growth, but it suppresses LNCaP cell apoptosis.**a** The CCK-8 assay indicated that the proliferation of LNCaP cells transfected with miR-188-5p mimics was significantly greater than that of cells transfected with the negative control. **b** The transwell assay showed that the enforced expression of miR-188-5p significantly enhanced the invasive activities of LNCaP cells compared with those of control cells. **c** The wound-healing assay revealed that miR-188-5p overexpression efficiently enhanced the migratory ability of LNCaP cells. **d** The apoptotic rate of LNCaP cells with miR-188-5p upregulation was significantly lower than that of control cells. **e--h** Knockdown of miR-188-5p expression by the corresponding inhibitor efficiently weakened the cellular proliferation, invasion ability and motility of LNCaP cell lines and inhibited the growth of tumor xenografts, but it enhanced cellular apoptosis qin vitro. Note: '×10' and '×20' refer to the magnification

In the rescue experiments, the endogenous expression of UBE2I protein in LNCaP and PC3 cells transfected with miR-188-5p mimics in the presence of pCDNA3.1-UBE2I was significantly higher than that in cells transfected with miR-188-5p and vector control (Fig. [6a](#Fig6){ref-type="fig"} and Supplementary Figure [S10A](#MOESM12){ref-type="media"}). In vitro cellular proliferation (Fig. [6b](#Fig6){ref-type="fig"} and Supplementary Figure [S10B](#MOESM12){ref-type="media"}), invasion (Fig. [6c](#Fig6){ref-type="fig"} and Supplementary Figure [S10C](#MOESM12){ref-type="media"}), migration (Fig. [6d](#Fig6){ref-type="fig"} and Supplementary Figure [S10D](#MOESM12){ref-type="media"}), and apoptosis (Fig. [6e](#Fig6){ref-type="fig"} and Supplementary Figure [S10E](#MOESM12){ref-type="media"}) all indicated that restoration of UBE2I expression dramatically attenuated the effects induced by miR-188-5p.Fig. 6Re-expression of UBE2I rescues the oncogenic effects of miR-188-5p in LNCaP cells.**a** Endogenous UBE2I protein expression levels were detected by western blotting in LNCaP cells transfected with the miR-188-5p mimic in the presence of UBE2I or vector control for 48 h. **b--e** Expression of UBE2I using a construct lacking its 3′-UTR rescued the biological effects associated with re-introduction of miR-188-5p, as indicated by cell invasion, viability, migration and apoptosis assays. These experiments were performed after co-transfection of miR-188-5p mimics and/or the UBE2I 3′-UTR (−) for 48 h. The data are representative of at least three independent experiments and are presented as the mean ± s.e.m. Note: '×10' and '×20' refer to the magnification

These findings suggest that the onco-miRNA roles of miR-188-5p may be mediated by inhibiting its target gene, UBE2I.

CCND1, RNASEL, CDKN1A, and MDM2 function as the downstream effectors of the miR-193a-5p-TP73 and miR-188-5p-UBE2I axes {#Sec10}
----------------------------------------------------------------------------------------------------------------------

According to our above-mentioned network analysis, the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I axis may play crucial roles in the imbalanced miRNA-mediated regulatory network of human PCa. After validation of the clinical significance and the biological functions of the miR-193a-5p-TP73 and miR-188-5p-UBE2I axes, we investigated their regulatory effects on the protein expression levels of CCND1, RNASEL, CDKN1A, and MDM2 by western blot analysis. As shown in Fig. [7a and b](#Fig7){ref-type="fig"}, the enforced expression of miR-193a-5p in two PCa cell lines, LNCaP and PC3, significantly reduced the protein expression levels of TP73, CCND1 and MDM2 but increased the protein expression levels of RNASEL and CDKN1A (all *P* \< 0.05). In contrast, miR-188-5p overexpression markedly increased the protein expression levels of CCND1 and MDM2 but decreased the protein expression levels of UBE2I, RNASEL and CDKN1A (all *P* \< 0.05). In addition, the expression levels of CCND1 and MDM2 proteins were dramatically upregulated, but the expression levels of RNASEL and CDKN1A proteins were significantly downregulated, in LNCaP and PC3 cells with the overexpression of TP73 (all *P* \< 0.05, Fig. [7c](#Fig7){ref-type="fig"}), which were opposite to the miR-193a-5p enforced cells. Moreover, the enforced expression of UBE2I in two PCa cell lines markedly reduced the protein expression levels of CCND1 and MDM2 but increased the protein expression levels of RNASEL and CDKN1A (all *P* \< 0.05, Fig. [7d](#Fig7){ref-type="fig"}), which were also opposite to the miR-188-5p enforced cells as mentioned above. Furthermore, the qPCR analysis shown in Supplementary Figure [S11](#MOESM13){ref-type="media"} also indicated the similar results to the western blot as mentioned above (Fig. [7](#Fig7){ref-type="fig"}). These findings suggest that CCND1, RNASEL, CDKN1A, and MDM2 may function as the downstream effectors of the miR-193a-5p-TP73 and miR-188-5p-UBE2I axes.Fig. 7Western blot analysis indicated that CCND1, RNASEL, CDKN1A and MDM2 function as the downstream effectors of the miR-193a-TP73 and miR-188-UBE2I axes at a protein level.**a** Relative protein expression levels of TP73, CCND1, RNASEL, CDKN1A, and MDM2 in LNCaP and PC3 cells transfected with miR-193a/NC-mimics. **b** Relative protein expression levels of UBE2I, CCND1, RNASEL, CDKN1A, and MDM2 in LNCaP and PC3 cells transfected with miR-188/NC-mimics. **c** Relative protein expression levels of TP73, CCND1, RNASEL, CDKN1A, and MDM2 in LNCaP and PC3 cells transfected with TP73/NC-expression vector. **d** Relative protein expression levels of UBE2I, CCND1, RNASEL, CDKN1A, and MDM2 in LNCaP and PC3 cells transfected with UBE2I/NC-expression vector. The data are representative of at least three independent experiments and are presented as the mean ± s.e.m. \**P* \< 0.05, compared with the normal control group; \*\**P* \< 0.01, compared with the normal control group

Discussion {#Sec11}
==========

miRNA dysregulation is a hallmark characteristic during prostate carcinogenesis. However, the underlying mechanisms of the miRNA-regulated oncogenic biomodules in PCa have not been fully elucidated. Previously, we identified a list of aberrantly expressed miRNAs based on a clinical cohort of PCa patients using an miRNA microarray approach. In this study, we constructed an miRNA-mediated gene expression regulatory network of PCa and identified a novel miRNA--mRNA regulatory biomodule of miR-193a-5p- and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signaling. Following network topological analysis, clinical significance evaluation and a series of functional experimental validations, we demonstrated that an imbalance in this biomodule may be implicated in prostate carcinogenesis, progression and patient prognosis.

Accumulating studies have reported the downregulation of miR-193a in various human cancers and revealed its involvement in carcinogenesis and cancer progression^[@CR21]--[@CR25]^. Similarly, our clinical analysis showed that dysregulation of the miR-193a/TP73 axis was closely correlated with advanced T-stage and positive disease recurrence. In addition, the BCR-free survival of PCa patients with miR-193a-5p-low/TP73-high expression was shorter than that of patients with miR-193a-5p-high/TP73-low expression. Functional experiments identified TP73 as a target gene of miR-193a-5p and confirmed the TP73-mediated tumor suppressive roles of the miR-193a-5p/TP73 axis in malignant PCa cell lines. More interestingly, Jacques et al.^[@CR25]^ found that miR-193a-5p controls Cisplatin chemoresistance in primary bone tumors via TAp73β. However, our data showed a more significant regulatory effect of miR-193a-5p on deltaNp73 (a tumor promoter isoform of TP73) than on TAp73 (a tumor suppressive isoform of TP73), implying different regulatory mechanisms of miR-193a-5p across cancer types.

miR-188, a cancer-related miRNA, functions as a tumor suppressor in oral squamous cell carcinoma^[@CR26]^ and hepatocellular carcinoma^[@CR27]^. Notably, Zhang et al.^[@CR28]^ suggested that miR-188-5p might exert tumor suppressor functions in the carcinogenesis of PCa, which disagrees with our findings. The reasons for this discrepancy might are explained below. First, the microarray data showing the marked upregulation of miR-188-5p in PCa tissues compared with adjacent non-cancerous prostate tissues were based on clinical samples. In contrast, Zhang's miRNA array data displaying the decreased expression of miR-188-5p were obtained from paired metastatic LTL-313H and non-metastatic LTL-313B PCa xenografts. Second, the TCGA data set used in our statistical analysis included 490 PCa samples, which is greater than the sample number in Zhang's clinical cohort (*n* = 180). Using this larger data set, we demonstrated that high-miR-188-5p and/or low-UBE2I expression was significantly associated with aggressive PCa progression and poor patient prognosis. Third, both groups used the same PCa cell lines (PC3 and LNCaP) to perform a series of in vitro and in vivo functional experiments. However, different findings were obtained, which may be due to the heterogeneity of cancer cells in different experimental platforms. Therefore, further large-scale validations are needed in the future.

We also determined the downstream effectors of the miR-193a-5p/TP73 and miR-188-5p/UBE2i axes. CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signaling was identified as a bottleneck in the miRNA-mediated gene expression regulatory network of PCa, which represents key interactions with surprising functional and dynamic properties^[@CR29]^. Based on the molecular interactions and the implications of this signaling in cancer^[@CR11]--[@CR20],[@CR30]^, we illustrated a biomodule of miR-193a-5p- and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signaling in Fig. [1b](#Fig1){ref-type="fig"}. Our experimental validations further confirmed the regulatory effects of miR-193a-5p and miR-188-5p on this signaling axis at both mRNA and protein levels.

Collectively, this integrated analysis of an miRNA-mediated gene expression regulatory network reveals the potential roles of miR-193a-5p/TP73 and miR-188-5p/UBE2i negative regulation pairs in PCa. Our data showed that miR-193a-5p and miR-188-5p targeted TP73 and UBE2I respectively at mRNA and protein level, suggesting that the two miRNAs may not work at the translational level throughout a DICER mechanism. In addition to the significant clinical relevance, miR-193a-5p- and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signaling may be a novel regulatory biomodule within prostate carcinogenesis. However, there are several limitations in the clinical cohort using in this study. For example, only 71 in 490 (14.5%) PCa patients occurred BCR; Only 10 in 490 (2.0%) patients died of PCa during the follow-up of overall survival. The imbalance of the feature distribution in this TCGA cohort might lead to the minor clinical relevance of the two miRNA/target pairs. Therefore, further prognostic evaluation based on other independent and large cohorts in compliance with statistical standard are required.

Methods {#Sec12}
=======

miRNA-mediated gene expression regulatory network analysis {#Sec13}
----------------------------------------------------------

A miRNA-mediated gene expression regulatory network was constructed based on the links between miRNAs and the corresponding putative target genes and the interactions among the putative target genes (Supplementary File [S1](#MOESM2){ref-type="media"}---sections [2--4](#MOESM2){ref-type="media"}).

Four topological features of nodes, including 'Degree,' 'Node betweenness,' 'Closeness' and 'K coreness,' and one topological feature of edges (links among nodes), namely, 'Edge betweenness,' were calculated to assess the topological importance of nodes and edges in the miRNA-mediated gene expression regulatory network. Each feature mentioned above is defined in Supplementary File [S1](#MOESM2){ref-type="media"}---section [5](#MOESM2){ref-type="media"}.

In addition, functional modularity was analyzed using the Markov clustering algorithm to identify nodes that are highly interconnected within the miRNA-mediated gene expression regulatory network and are generally involved in the same functional modules or biological pathways.

TCGA miRNA/mRNA data sets {#Sec14}
-------------------------

The expression profiles of miRNAs and mRNAs and clinical information for a cohort of 490 patients with primary PCa were retrieved from The Cancer Genome Atlas (TCGA, Provisional, <http://cancergenome.nih.gov>, Supplementary Table [S6](#MOESM19){ref-type="media"}). A language package for R was used to perform data statistical analysis.

Survival analysis {#Sec15}
-----------------

Follow-up data of all patients with primary PCa were collected from TCGA. The overall survival was calculated from the date of surgery to the date of the last follow-up or death. The biochemical recurrence (BCR)-free survival was defined as the interval between the time of the initial surgery and the date of the first occurrence of detectable consecutive increases in PSA levels. The distant-metastasis-free survival was determined as the interval from the time of the initial surgery to the observation date of metastatic lesions.

Cell culture {#Sec16}
------------

Two human PCa cell lines, LNCaP and PC3, were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium (HyClone, Los Angeles, CA, USA) supplemented with 10% fetal bovine serum (GIBCO/Invitrogen, Carlsbad, CA, USA), 2 mM [l]{.smallcaps}-glutamine, and antibiotics. A normal human prostate epithelial cell line (PREC) was purchased from Lonza Company and cultured in PrEGM Bullet kit (Lonza, Allendale, NJ, USA) with antibiotics. All cell lines were maintained at 37 °C in a humidified chamber supplemented with 5% CO~2~.

Animals {#Sec17}
-------

All animal experiments were performed according to the guidelines of the Institute for Laboratory Animal Research at Guangzhou Medical University, Guangzhou, P.R. China. BALB/c nude mice (4--5-week-old males) were obtained from Guangdong Medical Laboratory Animal Center and were housed five per cage in wire-top cages with sawdust bedding in an isolated, clean, air-conditioned room at a temperature of 25--26 °C, a relative humidity of \~50% and with a 12 h light cycle/day.

Cellular transfection {#Sec18}
---------------------

Commercial miR-188-5p mimics (miR-188-mimic, Cat. No.: miR10005301-1-5), miR-193a-5p mimics (miR-193a-mimic, Cat. No.: miR10000459-1-5), miRNA mimic control (NC-mimic, Cat. No.: miR01101-1-5), miR-188-5p inhibitor (anti-miR-188, Cat. No.: miR20005301-1-5), miR-193a-5p inhibitor (anti-miR-193a, Cat. No.: miR20000459-1-5), and a nonspecific anti-miRNA control (anti-NC, Cat. No.: miR02201-1-5) were purchased from RiboBio (Guangzhou, China). The pCDNA3.1-UBE2i and pCDNA3.1-TP73 vectors were generated by cloning the ORFs of the *UBE2i* and*TP73* genes into the pCDNA3.1 vector, performed by HYYMed (Guangzhou, China), and the pCDNA3.1 backbone vector was used as a blank control vector. These vectors were transfected into PCa cells using Lipofectamine 2000 reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol.

Generation of the in vivo xenograft model {#Sec19}
-----------------------------------------

LNCaP cells transfected with miR-188-5p/miR-193a-5p, miR-NC, anti-miR-188-5p/miR-193a-5p, or anti-NC lentivectors were used to construct the xenograft model of PCa for the in vivo tumor formation assay, as described in our previous studies^[@CR5],[@CR6]^. Detailed information on model construction and tumor volume calculation is provided in Supplementary File [S1](#MOESM2){ref-type="media"}---section [6](#MOESM2){ref-type="media"}.

Quantitative reverse transcription-PCR (qRT-PCR) {#Sec20}
------------------------------------------------

The qRT-PCR analyses for miRNAs and mRNAs in different cells were performed as described in our previous studies^[@CR5],[@CR6],[@CR31]^. The primer sequences are listed in Supplementary Table [S7](#MOESM20){ref-type="media"}.

Western blotting {#Sec21}
----------------

Western blot analysis was performed as described in our previous studies^[@CR5],[@CR6],[@CR31]^. Detailed information of the specific antibodies is provided in Supplementary Table [S8](#MOESM21){ref-type="media"}.

Luciferase reporter assay {#Sec22}
-------------------------

Luciferase reporter assay was performed to confirm direct binding efficiency of miRNAs and the corresponding target mRNA as described in our previous studies^[@CR5],[@CR6],[@CR31]^. Detailed information is provided in Supplementary File [S1](#MOESM2){ref-type="media"}---section [7](#MOESM2){ref-type="media"}.

Cell viability assay {#Sec23}
--------------------

Cell viability of PCa cells transfected with different vectors was detected with a Cell Counting Kit-8 (CCK-8, Cat No. C0037, Beyotime Biotechnology, Jiangsu, China) assay according to the protocol described in our previous studies^[@CR5],[@CR6],[@CR32]^.

Cell invasion and migration assays {#Sec24}
----------------------------------

The cell invasion and migration abilities of PCa cells transfected with different vectors were detected by the transwell and the scratch wound-healing motility assays, respectively, according to the protocol described in our previous studies^[@CR5],[@CR6],[@CR32]^.

Apoptosis assay {#Sec25}
---------------

Cell apoptosis of PCa cells transfected with different vectors was detected using the APC-conjugated Annexin V (Annexin V-APC)/7-aminoactinomycin D (7-AAD) Kit (Cat. No.: LK-AP104-60, Multi Sciences (Lianke) Biotech Co., Ltd., Hangzhou, China) according to the protocol described in our previous studies^[@CR5],[@CR6],[@CR32]^.

Statistical analysis {#Sec26}
--------------------

SPSS version 13.0 for Windows (SPSS Inc., IL, USA) was used for all statistical analyses in this study. All assays were performed in triplicate. Continuous variables are expressed as the mean ± s.e.m. Differences in the qRT-PCR and western blot data for different groups were evaluated using the Wilcoxon signed-rank test. The associations between miRNA/mRNA expression and various clinicopathological features of PCa patients were confirmed by two biostatisticians with Fisher's exact test for any 2 × 2 tables and the Pearson *χ*^2^-test for non-2 × 2 tables. A Kaplan--Meier curve was used for the survival analysis, and the Cox regression model was used for the univariate and multivariate analyses. The Spearman correlation was calculated between the expression levels of miRNAs and the corresponding target mRNAs in PCa tissues. Differences were considered significant when the *p*-value was \<0.05.
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